Parents FLEXtraNet

Reimbursement Tutorial

INOMAX^® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

INOMAX Important Safety Information (ISI)
INOMAX must not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood

Read Full ISI

Reimbursement Tutorial

Please complete the form below to access the Tutorial – and learn more about INOMAX and INOtherapy, the reimbursement process including everything from codes to contracts, and how our National Accounts Team can support you.

References

© 2012 Ikaria, Inc.
Ikaria Corporate Headquarters
Perryville III Corporate Park | 53 Frontage Road, Third Floor | PO Box 9001 | Hampton, NJ
Tel: 908-238-6600 | Fax: 908-238-6633

INOMAX^®, INOvent^®, INOtherapy^®, INOcal^®, and INOmeter^®are registered trademarks of INO Therapeutics LLC.

DS_IR^® is a registered trademark of Ikaria, Inc.

The product information provided in this site is intended only for residents of the United States.
The product discussed herein may have different product labeling in different countries.

INOMAX Important Safety Information

INOMAX must not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration. Caution should be used when administering INOMAX with other drugs that can cause methemoglobinemia regardless of their route of administration
Nitrogen dioxide (NO₂) rapidly forms in gas mixtures containing nitric oxide and oxygen. NO₂ formed in this way can cause airway inflammation and damage
INOMAX must be administered through a system that does not cause excessive generation of NO₂ and that monitors for NO, NO₂, and FiO₂
Abrupt discontinuation of INOMAX therapy can lead to worsening of PaO₂ and increasing pulmonary artery pressure (PAP). Deterioration in oxygenation and elevation in PAP can also occur in children with no apparent response to INOMAX
In patients with pre-existing left ventricular dysfunction, inhaled nitric oxide may increase pulmonary capillary wedge pressure leading to pulmonary edema

Please see Full Prescribing Information.

Refer a Colleague to INOMAX^®

Disclaimer

*Please note: When you access these resources, you are leaving the INOMAX website. Therefore, Ikaria Inc. does not endorse the accuracy of the information you may find. We encourage you to talk to your doctor about the accuracy of any information you discover through these Internet resources.

Agree and continue →

Reimbursement Tutorial

Reimbursement Tutorial

References

Refer a Colleague to INOMAX®

Get INOMAX® Email Updates

Disclaimer

Refer a Colleague to INOMAX^®

Get INOMAX^® Email Updates